Asthma/COPD Deck 3

Question 1

Tiotropium is a

Answer 1

Long-acting, inhaled anticholinergic agent approved
for maintenance therapy of bronchospasm associated
with COPD

Question 2

Tiotropium is not approved for

Answer 2

asthma

Question 3

Tiotropium action

Answer 3

Relieves bronchospasm by blocking muscarinic

receptors in the lung

Question 4

Tiotropium Theraputic effects begin about

Answer 4

30 minutes after

inhalation, peak in 3 hours, and persist about 24 hours

Question 5

Tiotropium with susequent doses

Answer 5

With subsequent doses: Bronchodilation continues to
improve, reaching a plateau after eight consecutive
doses (8 days)

Question 6

Tiotropium ADR

Answer 6

AE: dry mouth

• Minimal anti-cholinergic effects

Question 7

Aclindinium is the

Answer 7

Newest long-acting anticholinergic for
management of bronchospasm associated
with COPD

Question 8

Aclindinium relieves

Answer 8

• Relieves bronchospasm by blocking

muscarinic receptors in the lung

Question 9

Aclindinium peak

Answer 9

Peak levels have occurred within 10 minutes

of drug delivery

Question 10

Aclindinium intened only for

Answer 10

• Intended only for maintenance therapy

Question 11

Aclindinium not for

Answer 11

Not for acute symptom relief

Question 12

Aclindinium ADR

Answer 12

HA, nasopharyngitis, cough

Question 13

Glucocorticoid/LABA

Combinations availible

Answer 13

– Fluticasone/salmeterol [Advair]
– Budesonide/formoterol [Symbicort]
– Mometasone/formoterol [Dulera]

Question 14

Glucocorticoid/LABA

Combinations indicated

Answer 14

for long-term maintenance in

adults and children

Question 15

Phosphodiesterase-4 Inhibition reduce

Answer 15

Reduce risk of COPD exacerbations in

patients with a history of frequent COPD

Question 16

Phosphodiesterase-4 Inhibition decrease

Answer 16

Decreases inflammation and may promote

airway smooth muscle relaxation

Question 17

Phosphodiesterase-4 Inhibition example

Answer 17

Roflumilast

Question 18

Phosphodiesterase-4 Inhibition may be associated

Answer 18

May be associated with an increase in
adverse psychiatric reaction, should be used
in caution in patients with a history of
depression.

Question 19

Phosphodiesterase-4 Inhibition SE

Answer 19

insomnia, diarrhea, nausea, vomiting,

weight loss, and dyspepsia.